{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:30:54Z","timestamp":1786739454227,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Myelofibrosis is a chronic myeloproliferative disorder primarily affecting older adults, and allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option. However, HSCT for myelofibrosis presents significant challenges, including high nonrelapse mortality (NRM) and an increased risk of graft failure. In this 20-year retrospective study, we evaluated outcomes for 32 myelofibrosis patients who underwent HSCT at our institution, with particular focus on a two-step transplant approach designed to optimize T-cell dosing by separating the lymphoid and myeloid graft components, with cyclophosphamide administered after the lymphoid infusion and before infusion of CD34-selected stem cells. Eighteen patients underwent transplantation using the two-step approach and demonstrated favorable outcomes, with 1-year and 5-year overall survival (OS) rates of 83% and 68%, respectively. NRM was reduced, with rates of 17% at 1 year and 23% at 5 years. Engraftment was robust, with median neutrophil and platelet recovery at 12 and 19 days, respectively, and a low graft failure rate of 5.9% despite the predominant use of reduced-intensity conditioning and haploidentical donors, compared with 17.5% graft failure among patients receiving a traditional one-step transplant. Across the entire cohort, OS was 66% at 1 year and 54% at 5 years, respectively, with NRM rates of 34% and 42% at 5 years, respectively. The cumulative incidence of grade 2\u20134 acute graft-versus-host disease (GVHD) and chronic GVHD was 17% each. These findings suggest that the two-step transplant platform is a viable and effective strategy for improving HSCT outcomes in myelofibrosis, providing lower NRM and favorable engraftment profiles. Further studies are warranted to validate these results and refine HSCT protocols to reduce transplant-related mortality and improve long-term survival in patients with myelofibrosis.<\/jats:p>","DOI":"10.4103\/hemoncstem.hemoncstem-d-25-00039","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:00:14Z","timestamp":1779440414000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis"],"prefix":"10.4103","volume":"19","author":[{"given":"Xia","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaik","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Filicko-O'Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Van Galen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"O'Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Flomenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"R1-20260623","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kroger","year":"2024","journal-title":"Lancet Haematol"},{"key":"R2-20260623","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"key":"R3-20260623","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ajh.25053","article-title":"Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"R4-20260623","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11899-015-0279-9","article-title":"Current challenges in stem cell transplantation in myelofibrosis","volume":"10","author":"Kroger","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"R5-20260623","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"R6-20260623","first-page":"2180","volume":"97","author":"Li","year":"2001","journal-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood"},{"key":"R7-20260623","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ajh.27252","article-title":"Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis","volume":"99","author":"Gagelmann","year":"2024","journal-title":"Am J Hematol"},{"key":"R8-20260623","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3324\/haematol.2022.281958","article-title":"Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"108","author":"Murthy","year":"2023","journal-title":"Haematologica"},{"key":"R9-20260623","doi-asserted-by":"crossref","first-page":"264","DOI":"10.5045\/br.2022.2022194","article-title":"Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis","volume":"57","author":"Kim","year":"2022","journal-title":"Blood Res"},{"key":"R10-20260623","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R11-20260623","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1182\/blood-2011-07-365338","article-title":"A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1\/2 trial performed with optimized T-cell dosing","volume":"118","author":"Grosso","year":"2011","journal-title":"Blood"},{"key":"R12-20260623","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bbmt.2014.12.019","article-title":"A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease","volume":"21","author":"Grosso","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-20260623","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/s41409-022-01780-w","article-title":"Outcomes of two-step haploidentical allogeneic stem cell transplantation in elderly patients with hematologic malignancies","volume":"57","author":"Bi","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"R14-20260623","doi-asserted-by":"crossref","first-page":"1237782","DOI":"10.3389\/fimmu.2023.1237782","article-title":"The two-step approach to allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Ibikunle","year":"2023","journal-title":"Front Immunol"},{"key":"R15-20260623","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R16-20260623","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"R17-20260623","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"R18-20260623","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"R19-20260623","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R20-20260623","first-page":"324","article-title":"Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies","volume":"3","author":"Long","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"key":"R21-20260623","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2018.04.071","article-title":"Total body irradiation: guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"101","author":"Wong","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-20260623","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"R23-20260623","doi-asserted-by":"crossref","first-page":"e812","DOI":"10.1097\/HS9.0000000000000812","article-title":"Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia working party of the EBMT","volume":"7","author":"Spyridonidis","year":"2023","journal-title":"Hemasphere"},{"key":"R24-20260623","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41409-020-01050-7","article-title":"Total body irradiation + fludarabine compared to busulfan + fludarabine as \u201creduced-toxicity conditioning\u201d for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the acute leukemia working party of the EBMT","volume":"56","author":"Giebel","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R25-20260623","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41409-023-01966-w","article-title":"Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years: a registry-based study by the Acute Leukemia Working Party of the EBMT","volume":"58","author":"Hirschbuhl","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"R26-20260623","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1200\/JCO.1995.13.12.2973","article-title":"Busulfan\/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia","volume":"13","author":"O\u2019Donnell","year":"1995","journal-title":"J Clin Oncol"},{"key":"R27-20260623","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbmt.2015.09.017","article-title":"A two-step haploidentical versus a two-step matched related allogeneic myeloablative peripheral blood stem cell transplantation","volume":"22","author":"Gaballa","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R28-20260623","doi-asserted-by":"crossref","first-page":"159.e1","DOI":"10.1016\/j.jtct.2021.12.013","article-title":"The two-step allogeneic stem cell transplantation approach results in rapid engraftment and excellent outcomes in patients with lymphoid malignancies","volume":"28","author":"Yang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R29-20260623","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"R30-20260623","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"R31-20260623","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","article-title":"Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia","volume":"103","author":"Elliott","year":"1998","journal-title":"Br J Haematol"},{"key":"R32-20260623","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2016.02.004","article-title":"Allogeneic transplantation for patients with advanced myelofibrosis: splenomegaly and high serum LDH are adverse risk factors for successful engraftment","volume":"16","author":"Gergis","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R33-20260623","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","article-title":"Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis","volume":"36","author":"Helbig","year":"2019","journal-title":"Med Oncol"},{"key":"R34-20260623","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1080\/10428194.2017.1321747","article-title":"Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis","volume":"58","author":"Kalman","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R35-20260623","doi-asserted-by":"crossref","first-page":"100964","DOI":"10.1016\/j.adro.2022.100964","article-title":"Pretransplant splenic irradiation in patients with myeloproliferative neoplasms","volume":"7","author":"Ponce","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"R36-20260623","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kroger","year":"2009","journal-title":"Blood"},{"key":"R37-20260623","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41409-024-02220-7","article-title":"Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"59","author":"Oechsler","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"R38-20260623","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R39-20260623","doi-asserted-by":"crossref","first-page":"49.e1","DOI":"10.1016\/j.jtct.2022.10.015","article-title":"Haploidentical hematopoietic cell transplantation for myelofibrosis in the ruxolitinib era","volume":"29","author":"Gambella","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-25-00039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:05Z","timestamp":1786735745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-25-00039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-25-00039","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-09-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}